ArticleFunctional & integrative genomics2026
Overexpression of NK4 suppresses hepatocellular carcinoma progression by inducing apoptosis and autophagy via MAPK pathway inhibition.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) remains a therapeutic challenge, necessitating novel treatment strategies. This study explored the antitumor activity and underlying mechanisms of NK4 overexpression in HCC. Utilizing engineered NK4-overexpressing HepG2 cells and a TPA-inducible TP-NK4 system evaluated in both HepG2 and MHCC97-H cells, we demonstrated that NK4 significantly inhibits HCC cell proliferation and migration in vitro. Furthermore, NK4 potently induced apoptotic cell death, as evidenced by the modulation of key regulators Bax and Bcl-2. Crucially, the induction of NK4 expression also promoted autophagy and attenuated tumor growth in a mouse xenograft model. Mechanistic analysis indicated that inhibition of the MAPK pathway is central to these anticancer effects. Our integrated findings establish NK4 as a potent multi-faceted inhibitor of HCC progression and highlight its strong therapeutic potential for precision oncology applications by targeting apoptosis, autophagy, and MAPK signaling.
Indexed as
Identifiers
41917646What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.